PRIMARY CENTRAL NERVOUS SYSTEM EFFUSION PLASMABLASTIC LYMPHOMA IN IMMUNOCOMPROMISED PATIENT: A RARE PHENOMENON

  • Brij Mohan Singh Department of Pathology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal - 576 104, Karnataka, India.
  • Sushma Belurkar Department of Pathology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal - 576 104, Karnataka, India.
  • Arijit Bishnu Department of Pathology, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal - 576 104, Karnataka, India.
  • Tanvi Shetty Department of Pathology, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal - 576 104, Karnataka, India.
  • Pavithra P Department of Pathology, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal - 576 104, Karnataka, India.

Abstract

Primary effusion lymphoma (PEL) is an aggressive neoplasm with a high rate of fatality. PEL cells are known to have morphological diversities, which range from immunoblastic or plasmablastic to anaplastic. Most of these cases are described in immunocompromised as well as immunocompetent patients. Plasmablastic lymphoma remains a diagnostic challenge, especially when encountered with the presentation as PEL. In spite of therapeutic advances, PEL remains an aggressive disease with a high rate of fatality. We describe one case of this extremely rare neoplasm in an immunocompromised patient presenting in the form of primary central nervous system effusion plasmablastic lymphoma. To the best of our knowledge, this is the first case ever been reported in the literature.

Keywords: Primary effusion lymphoma, Plasmablastic lymphoma, Papanicolaou smear, Flow cytometry.

Author Biography

Brij Mohan Singh, Department of Pathology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal - 576 104, Karnataka, India.
Department of Pathology Associate Professor

References

1. Parmar F, Kushawaha N, Highland H, George LB. In vitro antioxidant and anticancer activity of Mimosa pudica Linn extract and l-mimosine on lymphoma Daudi cells. Int J Pharm PharmSci 2015;7:100-4.
2. Sandler AS, Kaplan LD. Diagnosis and management of systemic non- Hodgkin’s lymphoma in HIV disease. Hematol Oncol Clin North Am 1996;10:1111.
3. Coté TR, Biggar RJ, Rosenberg PS, Devesa SS, Percy C, Yellin FJ, et al. Non-hodgkin’s lymphoma among people with AIDS: Incidence, presentation and public health burden. AIDS/Cancer study group. Int J Cancer 1997;73:645-50.
4. Wang CC, Kaplan LD. Clinical management of HIV-associated hematologic malignancies. Expert Rev Hematol 2016;9:361.
5. Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: A single-institution study. J Clin Oncol 2003;21:3948-54.
6. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2009. p. 256-7.
7. Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U, et al. Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413-20.
8. Dales JP, Harket A, Bagnères D, Andrac-Meyer L, Xerri L, Frances Y, et al. Plasmablastic lymphoma in a patient with HIV infection: An unusual case located in the skin. Ann Pathol 2005;25:45-9.
9. Liang R, Wang Z, Chen XQ, Bai QX. Treatment of plasmablastic lymphoma with multiple organ involvement. Singapore Med J 2014;55:e194-7.
10. Huang X, Zhang Y, Gao Z. Plasmablastic lymphoma of the stomach with C-MYC rearrangement in an immunocompetent young adult: A case report. Medicine (Baltimore) 2015;94:e470.
11. Romero M, González-Fontal GR, Saavedra C, Guerra J, Quintero G, Quijano S, et al. Primary CNS plasmablastic lymphoma in an HIV/ EBV negative patient: A case report. Diagn Cytopathol 2016;44:61-5.
12. Schichman SA, McClure R, Schaefer RF, Mehta P. HIV and plasmablastic lymphoma manifesting in sinus, testicles, and bones: A further expansion of the disease spectrum. Am J Hematol 2004;77:291-5.
13. Vasudevan G, Singh BM, Bishnu A, Kulshreshta A. Plasmablastic lymphoma: A report of 2 cases with review of literature. J Interdiscipl Histopathol 2016;4:74-8.
14. Stein H, Harris NL, Campo E. Plasmablastic lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2008. p. 256-7.
15. Colomo L, Loong F, Rives S, Pittaluga S, Martínez A, López- Guillermo A, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004;28:736-47.
16. Castillo JJ, Reagan JL. Plasmablastic lymphoma: A systematic review. Sci World J 2011;11:687-96.
17. Malathi J, Janani MK, Murugan N, Madhavan HN. Draft genome sequence of human herpes virus-4 VRF_EBV_01, an Epstein Barr virus obtained from a pediatric post-transplant lymphoproliferative disorder (PTLD) patient. Int J Pharm PharmSci 2015;7:513-4.
18. Kim Y, Park CJ, Roh J, Huh J. Current concept in primary effusion lymphoma and other effusion-based lymphoma. Korean J Pathol 2014;48:81-90.
Statistics
181 Views | 347 Downloads
Citatons
How to Cite
Singh, B. M., S. Belurkar, A. Bishnu, T. Shetty, and P. P. “PRIMARY CENTRAL NERVOUS SYSTEM EFFUSION PLASMABLASTIC LYMPHOMA IN IMMUNOCOMPROMISED PATIENT: A RARE PHENOMENON”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 8, Aug. 2018, pp. 6-7, doi:10.22159/ajpcr.2018.v11i8.24754.
Section
Case Study(s)